Theme: Social Science & Policy Research Year: 2018
In 2015, the Australian Government funded a national project to monitor stigma
among people living with blood borne viruses and sexually transmitted infections as
part of the national monitoring project to meet the goals of the National BBV/STI
Strategies. This project measured experienced stigma (among people living with
HCV and people who inject drugs) and expressed stigma (among health workers
and the general public).
A “stigma indicator” was applied to four groups of participants via online surveys: (1)
people who live with HCV (n=108); (2) people who inject drugs (n=124); (3) a
representative sample of the Australian population (n=900); (4) a sample of health
Results: More than half of participants reported experiencing stigma within the last
12 months related to their injecting drug use (59%) or hepatitis C status (56%). 17%
of people who inject drugs reported that they ‘often’ or ‘always’ experienced stigma
or discrimination compared to 6% in relation to hepatitis C status.
Among the general public, 87% indicated that they would behave negatively toward
someone who injected drugs and 66% indicated the same for people living with
While health workers reported infrequent instances of discrimination against people
with any of the attributes listed, discrimination against people who inject drugs was
more common than any other group (35%). Nearly half (43%) of health workers did
not feel stigmatised because of the area in which they were employed, though 36%
reported ‘sometimes’ or ‘often’ feeling stigmatised.
Stigma remains a salient experience and a critical barrier to treatment access and
ongoing care for affected communities, despite the availability of “better” HCV
treatments. These results will be discussed in relation to the key strategies from the
literature regarding stigma reduction interventions.
Disclosure of Interest Statement: None to report.